Drawing for NEUVASQ

USPTO serial 79439015

NEUVASQ

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BECHHOFER, YOCHEVED D
Law office
TMO LAW OFFICE 137

What this means

Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.

Status 680: Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose.

Need help with NEUVASQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Clifford D. Hyra

Clifford D. Hyra Fresh IP PLC11710 Plaza America Drive Suite 2000Reston, VA 20190United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals and medicines for the treatment and prevention of neurological disorders; pharmaceuticals and medicines for the treatment and prevention of neurodegenerative diseases; pharmaceutical preparations and substances for the treatment of eye diseases and conditions; pharmaceuticals and medicines for the treatment and prevention of bone disorders and conditions; medicated therapeutic preparations for the management of retinal disorders; injectable pharmaceuticals for the treatment of ocular diseases and neurological disorders.ACTIVE—
042Medical and pharmacological research services; pharmaceutical research and development of pharmaceuticals and medicines; pharmaceutical research and development of pharmaceutical products and medicines for the treatment and prevention of neurological disorders, eye diseases and bone disorders.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 8, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 8, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2026LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Mar 26, 2026RFNTREFUSAL PROCESSED BY IB—
Mar 6, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 6, 2026RFRRREFUSAL PROCESSED BY MPU—
Feb 5, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 4, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 29, 2026DOCKASSIGNED TO EXAMINER—
Dec 15, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 15, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 11, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance